(ITGR) Integer Holdings - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 3.031m USD | Total Return: -25.9% in 12m

Medical Devices, Implantable Components, Batteries, Lead
Total Rating 48
Safety 78
Buy Signal -0.05
Medical Devices
Industry Rotation: +5.3
Market Cap: 3.03B
Avg Turnover: 47.4M
Risk 3d forecast
Volatility29.1%
VaR 5th Pctl4.68%
VaR vs Median-2.80%
Reward TTM
Sharpe Ratio-0.49
Rel. Str. IBD26.4
Rel. Str. Peer Group53
Character TTM
Beta0.417
Beta Downside0.753
Hurst Exponent0.502
Drawdowns 3y
Max DD56.14%
CAGR/Max DD0.06
CAGR/Mean DD0.20
EPS (Earnings per Share) EPS (Earnings per Share) of ITGR over the last years for every Quarter: "2021-03": 0.97, "2021-06": 1.07, "2021-09": 1.05, "2021-12": 0.99, "2022-03": 0.78, "2022-06": 1.04, "2022-09": 0.95, "2022-12": 1.11, "2023-03": 0.87, "2023-06": 1.14, "2023-09": 1.27, "2023-12": 1.39, "2024-03": 1.14, "2024-06": 1.3, "2024-09": 1.43, "2024-12": 1.43, "2025-03": 1.31, "2025-06": 1.55, "2025-09": 1.79, "2025-12": 1.76, "2026-03": 1.2,
EPS CAGR: 16.65%
EPS Trend: 98.4%
Last SUE: 0.22
Qual. Beats: 0
Revenue Revenue of ITGR over the last years for every Quarter: 2021-03: 290.467, 2021-06: 312.023, 2021-09: 305.574, 2021-12: 313.015, 2022-03: 310.912, 2022-06: 350.081, 2022-09: 342.68, 2022-12: 373.195, 2023-03: 378.785, 2023-06: 399.763, 2023-09: 396.803, 2023-12: 404.504, 2024-03: 407.796, 2024-06: 427.886, 2024-09: 431.417, 2024-12: 449.497, 2025-03: 436.167, 2025-06: 472.831, 2025-09: 466.573, 2025-12: 470.895, 2026-03: 439.58,
Rev. CAGR: 8.29%
Rev. Trend: 99.4%
Last SUE: 2.01
Qual. Beats: 1

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: ITGR Integer Holdings

Integer Holdings Corporation (ITGR) is a major medical device contract development and manufacturing organization (CDMO) headquartered in Plano, Texas. The company provides end-to-end design and manufacturing services for original equipment manufacturers (OEMs) across various clinical areas, including cardiovascular, neuromodulation, and orthopedics. Its product portfolio encompasses critical components such as implantable batteries, leads, and enclosures, as well as finished devices like pacemakers and ventilators.

The medical CDMO sector is characterized by high barriers to entry due to stringent regulatory requirements and the technical complexity of miniaturized implantable technologies. Integer operates under the Greatbatch Medical and Lake Region Medical brands, leveraging a global manufacturing footprint that includes facilities in the United States, Ireland, and Costa Rica to support large-scale production for multinational healthcare firms.

Interested parties may find ValueRay useful for deeper quantitative analysis of the companys fundamentals.

Headlines to Watch Out For
  • Increased demand for interventional cardiology and structural heart devices drives revenue growth
  • Expansion of contract manufacturing capacity improves operating margins and scalability
  • Consolidation among medical device OEMs impacts long-term outsourcing and supply contracts
  • Supply chain stability and raw material costs affect manufacturing profitability
  • Growth in neurostimulation and neuromodulation markets accelerates specialized component sales volume
Piotroski VR-10 (Strict) 5.5
Net Income: 141.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.84 > 1.0
NWC/Revenue: 30.73% < 20% (prev 28.41%; Δ 2.31% < -1%)
CFO/TA 0.06 > 3% & CFO 189.6m > Net Income 141.8m
Net Debt (1.50b) to EBITDA (328.4m): 4.58 < 3
Current Ratio: 3.75 > 1.5 & < 3
Outstanding Shares: last quarter (34.4m) vs 12m ago 1.52% < -2%
Gross Margin: 23.31% > 18% (prev 0.26%; Δ 2.31k% > 0.5%)
Asset Turnover: 55.14% > 50% (prev 52.91%; Δ 2.23% > 0%)
Interest Coverage Ratio: 5.07 > 6 (EBITDA TTM 328.4m / Interest Expense TTM 38.0m)
Altman Z'' 3.09
A: 0.17 (Total Current Assets 774.8m - Total Current Liabilities 206.3m) / Total Assets 3.41b
B: 0.30 (Retained Earnings 1.01b / Total Assets 3.41b)
C: 0.06 (EBIT TTM 192.6m / Avg Total Assets 3.35b)
D: 0.62 (Book Value of Equity 1.06b / Total Liabilities 1.71b)
Altman-Z'' = 3.09 = A
Beneish M -3.06
DSRI: 0.82 (Receivables 327.8m/379.2m, Revenue 1.85b/1.74b)
GMI: 1.13 (GM 23.31% / 26.24%)
AQI: 0.96 (AQ_t 0.57 / AQ_t-1 0.60)
SGI: 1.06 (Revenue 1.85b / 1.74b)
TATA: -0.01 (NI 141.8m - CFO 189.6m) / TA 3.41b)
Beneish M = -3.06 (Cap -4..+1) = AA
What is the price of ITGR shares?

As of May 27, 2026, the stock is trading at USD 90.14 with a total of 999,766 shares traded.
Over the past week, the price has changed by +0.19%, over one month by +5.61%, over three months by +3.88% and over the past year by -25.89%.

Is ITGR a buy, sell or hold?

Integer Holdings has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy ITGR.

  • StrongBuy: 7
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ITGR price?
Analysts Target Price 97.2 7.9%
Integer Holdings (ITGR) - Fundamental Data Overview as of 26 May 2026
Market Cap USD = 3.03b (3.03b USD * 1.0 USD.USD)
P/E Trailing = 22.1538
P/E Forward = 19.1205
P/S = 1.6335
P/B = 1.7865
P/EG = 2.3897
Revenue TTM = 1.85b USD
EBIT TTM = 192.6m USD
EBITDA TTM = 328.4m USD
Long Term Debt = 1.25b USD (from longTermDebt, last quarter)
Short Term Debt = 8.11m USD (from shortTermDebt, last quarter)
Debt = 1.51b USD (from shortLongTermDebtTotal, last quarter) + Leases 129.9m
Net Debt = 1.50b USD (calculated: Debt 1.51b - CCE 8.12m)
Enterprise Value = 4.53b USD (3.03b + Debt 1.51b - CCE 8.12m)
Interest Coverage Ratio = 5.07 (Ebit TTM 192.6m / Interest Expense TTM 38.0m)
EV/FCF = 31.49x (Enterprise Value 4.53b / FCF TTM 144.0m)
FCF Yield = 3.18% (FCF TTM 144.0m / Enterprise Value 4.53b)
FCF Margin = 7.79% (FCF TTM 144.0m / Revenue TTM 1.85b)
Net Margin = 7.67% (Net Income TTM 141.8m / Revenue TTM 1.85b)
Gross Margin = 23.31% ((Revenue TTM 1.85b - Cost of Revenue TTM 1.42b) / Revenue TTM)
Gross Margin QoQ = 24.93% (prev 22.53%)
Tobins Q-Ratio = 1.33 (Enterprise Value 4.53b / Total Assets 3.41b)
Interest Expense / Debt = 2.51% (Interest Expense 38.0m / Debt 1.51b)
Taxrate = 18.89% (3.85m / 20.4m)
NOPAT = 156.2m (EBIT 192.6m * (1 - 18.89%))
Current Ratio = 3.75 (Total Current Assets 774.8m / Total Current Liabilities 206.3m)
Debt / Equity = 0.89 (Debt 1.51b / totalStockholderEquity, last quarter 1.70b)
Debt / EBITDA = 4.58 (Net Debt 1.50b / EBITDA 328.4m)
Debt / FCF = 10.44 (Net Debt 1.50b / FCF TTM 144.0m)
Total Stockholder Equity = 1.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.23% (Net Income 141.8m / Total Assets 3.41b)
RoE = 8.23% (Net Income TTM 141.8m / Total Stockholder Equity 1.72b)
RoCE = 6.47% (EBIT 192.6m / Capital Employed (Equity 1.72b + L.T.Debt 1.25b))
RoIC = 4.86% (NOPAT 156.2m / Invested Capital 3.21b)
WACC = 5.65% (E(3.03b)/V(4.54b) * Re(7.45%) + D(1.51b)/V(4.54b) * Rd(2.51%) * (1-Tc(0.19)))
Discount Rate = 7.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 2.22 | Cagr: 0.58%
[DCF] Terminal Value 77.97% ; FCFF base≈131.0m ; Y1≈150.2m ; Y5≈221.0m
[DCF] Fair Price = 53.68 (EV 3.33b - Net Debt 1.50b = Equity 1.82b / Shares 34.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.42 | EPS CAGR: 16.65% | SUE: 0.22 | # QB: 0
Revenue Correlation: 99.38 | Revenue CAGR: 8.29% | SUE: 2.01 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.38 | Chg30d=-10.30% | Revisions=-67% | Analysts=8
EPS next Quarter (2026-09-30): EPS=1.69 | Chg30d=-8.15% | Revisions=-67% | Analysts=8
EPS current Year (2026-12-31): EPS=6.08 | Chg30d=-6.29% | Revisions=-69% | GrowthEPS=-5.0% | GrowthRev=-2.0%
EPS next Year (2027-12-31): EPS=6.81 | Chg30d=-5.78% | Revisions=-67% | GrowthEPS=+11.9% | GrowthRev=+5.9%
[Analyst] Revisions Ratio: -69%